Table 2. Vinorelbine trials in second line mesothelioma.
| First author | Treatments | Patients | RR (%) | mTTP/mPFS (months) | mOS (months) |
|---|---|---|---|---|---|
| Stebbing J (12) | Vinorelbine 30 mg/mq weekly ×6 cycles | 63 | 16 | NR | 9.6 |
| Zucali PA (13) | Vinorelbine 25 mg/mq day 1, 8 every 21 | 59 | 15 | 2.3 | 6.2 |
| Zauderer MG (14) | Vinorelbine 25 mg/mq day 1, 8 every 21 | 45 | 0 | 2.5 | 5.0 |
| Sørensen JB (15) | Oral vinorelbine 80 mg/mq day 1, 8 every 21 | 15 | 7 | 2.3 | 2.5 |
| Zucali PA (16) | Vinorelbine 25 mg/mq + gemcitabine 1,000 mg/mq day 1, 8 every 21 | 30 | 10 | 2.8 | 10.9 |
| Toyokawa G (17) | Vinorelbine 25 mg/mq + gemcitabine 1,000 mg/mq day 1, 8 every 21 | 17 | 18 | 6.0 | 11.2 |
RR, response rate; mTTP, median time to progression; mPFS, median progression free survival; mOS, median overall survival; mg/mq, milligrams/square meter; NR, not reported.